{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.03","value":"11.0"},{"groupId":"OG001","spread":"1.04","value":"10.3"},{"groupId":"OG002","spread":"0.8","value":"10.6"},{"groupId":"OG003","spread":"0.96","value":"10.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"}],"units":"Participants"}],"description":"To compare the effects of the 3 different epoetin alfa dosing schedules and an every-3-weeks darbepoetin alfa schedule. The positive numbers represent hemoglobin increases and negative numbers represent hemoglobin decreases.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)","id":"OG000","title":"Epoetin Alfa - 40k Weekly"},{"description":"Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)","id":"OG001","title":"Epoetin Alfa - 80k Every 3 Weeks"},{"description":"Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)","id":"OG002","title":"Epoetin Alfa - 120k Every 3 Weeks"},{"description":"Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)","id":"OG003","title":"Darbepoetin Alfa - 500 mcg Every 3 Weeks"}],"paramType":"MEAN","populationDescription":"All patients that were evaluable per protocol and had hemoglobin data.","reportingStatus":"POSTED","timeFrame":"Week 1 and Week 16","title":"Mean Hemoglobin Change From Week 1 to Week 16","type":"SECONDARY","unitOfMeasure":"g/dL"}